Literature DB >> 17981654

Humanization of antibodies.

Juan C Almagro1, Johan Fransson.   

Abstract

Humanization has played a fundamental role in the remarkable progress of antibodies as therapeutic reagents. Here we have reviewed the publications on antibody humanization since the first report on CDR grafting in the second half of the 1980's up to June 2007. We describe the two main trends in the field: rational and empirical methods to humanize antibodies. Rational methods rely on the so-called design cycle. It consists of generating a small set of variants, which are designed based on the antibody structure and/or sequence information, and assessing their binding or any other characteristic of interest. Rational methods include CDR grafting, Resurfacing, Superhumanization and Human String Content Optimization. In contrast to rational methods, empirical methods are based on generating large combinatorial libraries and selecting the desired variants by enrichment technologies such as phage, ribosome or yeast display, or by high throughput screening techniques. The latter methods rest on selection rather than making assumptions on the impact of mutations on the antibody structure. These methods include Framework Libraries, Guided Selection, Framework Shuffling and Humaneering.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981654     DOI: 10.2741/2786

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  76 in total

Review 1.  Targeting the embryonic gene Cripto-1 in cancer and beyond.

Authors:  Caterina Bianco; David S Salomon
Journal:  Expert Opin Ther Pat       Date:  2010-11-13       Impact factor: 6.674

2.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

3.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

Review 4.  Animal pharming, two decades on.

Authors:  Alexander Kind; Angelika Schnieke
Journal:  Transgenic Res       Date:  2008-07-29       Impact factor: 2.788

5.  New engineered antibodies against prions.

Authors:  Nives Škrlj; Marko Dolinar
Journal:  Bioengineered       Date:  2013-08-09       Impact factor: 3.269

6.  4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.

Authors:  Alain Beck; Sherif Hanala; Janice M Reichert
Journal:  MAbs       Date:  2009-03-20       Impact factor: 5.857

7.  Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells.

Authors:  Arsham Banisadr; Yaghoub Safdari; Anvarsadat Kianmehr; Mahdieh Pourafshar
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

8.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

Review 9.  The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy.

Authors:  J Griggs; K Zinkewich-Peotti
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

10.  Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.

Authors:  Thomas Müller; Bernhard Dietzschold; Hildegund Ertl; Anthony R Fooks; Conrad Freuling; Christine Fehlner-Gardiner; Jeannette Kliemt; Francois X Meslin; Richard Franka; Charles E Rupprecht; Noël Tordo; Alexander I Wanderler; Marie Paule Kieny
Journal:  PLoS Negl Trop Dis       Date:  2009-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.